Visceral adipose tissue mass
2 papers1 finding
- Human trial1
- Humans1
Interventions
1Pemvidutide
downin humans1−28%
1 study
Pemvidutide
downin humans1−28%
Pemvidutide decreases visceral adipose tissue mass in humans (-28.3%).
“VAT mass decreased by up to 28.3% at the 2.4 mg dose at Week 48.”
Human trialoverweight or obesityvisceral adipose tissue2.4 mg48 weeksn = 67
ADA Scientific Sessions 2025 abstract13 Jun 2025
Latest
4 in 12 monthsJournal of Clinical Medicine
Sarcopenic Obesity and Sex-Specific Functional Impairment in Older Adults: An Observational Case-Control Study
Case-control study of 85 peopleSarcopenic obesity
American Journal of Physiology Regulatory, Integrative and Comparative Physiology
Menopausal duration and relative skeletal muscle index predict metabolic inflexibility during walking in postmenopausal women with overweight/obesity
Cross-sectional study of 36 peopleObesity
medRxiv
Coffee Intake is Associated with Improved Insulin Sensitivity and Lower Visceral Adiposity: Evidence from Biomarker and Genetic Analysis
Preprint: cohort study of 333,053 peoplePopulations
ADA Scientific Sessions 2026 Abstract
Leukemia Inhibitory Factor Promotes the Adipogenesis of Age-Enriched Adipose Progenitor Cells
Experiments in human cellsMechanisms
ADA Scientific Sessions 2025 Abstract
Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide
Randomised trial in 67 peopleOverweight
Journal of the National Cancer Institute
Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study
Trial in peopleInterventions
GeroScience
The influence of a human macronutrient-matched diet on phenotypes in old mice
Experiments in animalsInterventions